Ideaya biosciences announces late-breaker oral presentation of ide397 phase 1 expansion results in mtap-deletion lung and urothelial cancer at the 36th edition of the eortc-nci-aacr symposium

South san francisco, calif. , oct. 4, 2024 /prnewswire/ -- ideaya biosciences, inc. (nasdaq:idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a late-breaking oral presentation of the phase 1 expansion results of ide397, a first-in-class, oral, mat2a inhibitor in methylthioadenosine phosphorylase (mtap)-deletion urothelial and non-small cell lung cancer (nsclc) patients at the 36th edition of the eortc-nci-aacr symposium on molecular targets and cancer therapeutics taking place on october 23 to 25, 2024, in barcelona, spain.
NCI Ratings Summary
NCI Quant Ranking